GW plans to price initial public sale of American Depositary Shares

Joint bookrunners Lazard Capital Markets and Cowen assist with sale

By Devika Patel

Knoxville, Tenn., March 19 - GW Pharmaceuticals plc plans to price its initial public offering of American Depositary Shares with a 30-day greenshoe, according to a Form F-1 filed Tuesday with the Securities and Exchange Commission.

Lazard Capital Markets and Cowen and Co. are the joint bookrunners. Canaccord Genuity is the lead manager, and Roth Capital Partners is the co-manager.

Proceeds will be used for new clinical trials of multiple product candidates, to expand the company's Sativex manufacturing capabilities, to discover and develop new product candidates, for research and development activities and for working capital and other general corporate purposes.

GW, based in Wiltshire, England, develops cannabis-derived pharmaceutical products for patients with multiple sclerosis, spinal cord injury, rheumatoid arthritis, neuropathic pain, cancer pain and other severe medical conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.